A Comparative Pharmacokinetic Study of Two Survodutide Formulations in Healthy Volunteers

The primary objective of this study is to compare the **pharmacokinetics** of two different formulations of survodutide in healthy individuals. This evaluation is clinically relevant as it provides insights into the absorption, distribution, metabolism, and excretion of the drug, which are critical for determining the optimal formulation for therapeutic use. Understanding these parameters is essential for ensuring efficacy and safety in future clinical applications.

The clinical trial involves **healthy volunteers** as the study population, with both male and female participants included. The age range of the participants is categorized as adults, although specific age limits are not provided. The trial does not focus on a vulnerable population, indicating that participants are likely in good general health. The total number of participants is not disclosed, as the sponsor has not provided this information. Selection criteria for the trial population, as well as any lifestyle considerations such as diet or physical activity, are not specified in the available data. Key inclusion or exclusion criteria are also not detailed, suggesting a broad eligibility for participation within the defined parameters of health and age. The trial is designed to assess outcomes in a general adult population without specific lifestyle or health condition restrictions.

The clinical trial is designed to evaluate the pharmacokinetics of two different formulations of **survodutide** in healthy volunteers. This study is a Phase 3, randomized, double-blind, controlled trial, ensuring that neither the participants nor the investigators are aware of the specific formulation being administered to each participant. The trial is expected to commence on July 28, 2025, with an estimated completion date of October 21, 2025, indicating a total duration of approximately three months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, potential participants will be assessed for eligibility based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized to receive one of the two formulations of survodutide. Subsequent follow-up visits will be scheduled to monitor the uptake of the drug in the body, assess safety, and collect necessary data for the study's endpoints. The end-of-study visit will mark the conclusion of the participant's involvement, where final assessments will be conducted to ensure participant safety and gather any remaining data.

The expected length of participant involvement in the trial is approximately three months, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are structured to ensure the collection of robust and reliable data while maintaining the safety and well-being of all participants involved.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The efficacy of the clinical trial will be assessed through a structured evaluation process. As the trial is in Phase 3, it is designed to confirm the effectiveness of the intervention in a larger population. The assessment will involve the collection and analysis of data at predetermined timepoints throughout the trial duration. The estimated recruitment start date is July 28, 2025, with an estimated end date of October 21, 2025. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and tools for measurement, are not detailed in the provided information. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.